DiamiR and AlzLabs Partner on Blood-Based Alzheimer's Biomarker Research
DiamiR Biosciences and AlzLabs Precision Diagnostics will jointly develop protein and microRNA blood biomarkers targeting Alzheimer's disease detection.
Aptorum Group Limited (NASDAQ: APM), a clinical-stage biopharmaceutical company, announced Monday that two of its affiliated ventures — DiamiR Biosciences Corp. and AlzLabs Precision Diagnostics — have entered a research collaboration aimed at generating blood-based biomarker data for Alzheimer's disease, with a specific focus on proteins and microRNA.
DiamiR, headquartered in New Haven, Connecticut, specializes in developing innovative blood-based diagnostic tests for brain health and other diseases. By pairing its platform with AlzLabs Precision Diagnostics, based in Princeton, New Jersey, the two companies intend to combine complementary expertise to advance early and accurate identification of Alzheimer's-related biological signals without invasive procedures.
Read more Tim Cook Warns of Rising iPhone Costs Due to Memory Prices →
The collaboration reflects a broader industry push toward less invasive, scalable diagnostics for neurodegenerative diseases. Blood-based biomarkers — particularly proteins and microRNA — have emerged as promising alternatives to costly PET scans and lumbar punctures traditionally used to detect Alzheimer's pathology, though the source does not specify a timeline or clinical milestones for this particular effort.
Aptorum Group, listed on the Nasdaq under the ticker APM and operating out of New York, positions itself as a company dedicated to addressing unmet medical needs. The announced partnership between DiamiR and AlzLabs represents a concrete step in translating that mission into actionable diagnostic tools for one of the world's most prevalent and costly neurological conditions.
Continue reading at GlobalNewswire.
